Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis

Bone Marrow Transplantation

Volumn 37, Issue 10, 2006, Pages 937-943

  Perz, Jolanta B ^a   Rahemtulla, A ^a   Giles, C ^a   Szydlo, R M ^a   Davis, J ^a   Gopaul, D ^b   Gillmore, J ^b   Mathias, C J ^c   Hawkins, P N ^b   Apperley, J F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autologous stem cell transplantation (ASCT); High dose melphalan (HDM); Light chain (AL) amyloidosis; Long term survival

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MELPHALAN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; HEART DISEASE; HEART TRANSPLANTATION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; KIDNEY AMYLOIDOSIS; LIGHT CHAIN; LUNG DISEASE; MEDICAL ASSESSMENT; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33646928321     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705354     Document Type: Article

References (24)

1. Kyle RA, Linos A, Mary Beard C, Linke RP, Gertz MA, O'Fallon M et al. Incidence and natural history of primary systemic amyloidosis (AL) in Olmsted Country, Minnesota: 1950-1989. Blood 1992; 79: 1817-1822.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 1997; 337: 898-909.
3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062-1066.
4. Skinner M, Anderson JJ, Simms R. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone and colchicine versus colchicine only. Am J Med 1996; 100: 290-298.
5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997; 336: 1202-1207.
6. Gertz MA, Lacy MQ, Lust JA, Greipp PP, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262-267.
7. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
8. Goodman HJB, Hawkins PN. The role of PBSCT in treatment of AL amyloidosis is far from settled. Blood 2004; 104: 2991.
9. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
10. Gillmore JD, Apperley JF, Craddock C. High-dose melphalan and stem cell recue for AL amyloidosis. In: Kyle RA, Gertz MA (eds). Amyloid and amyloidosis. Parthenon Publishing Group: New York & London, 1998, pp 102-104.
11. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282.
12. Gertz M, Lacy M, Gastineau DA, Inwards DJ, Chen MG, Teffei A et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis. Bone Marrow Transplantation 2000; 26: 963-969.
13. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549-555.
14. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004; 140: 85-93.
15. Jaccard A, Moreau P, Leblond V, Leleu X, Bebboubker L, Hermine O et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (Primary) amyloidosis: results of the French multicentric randomized trial (MAG and IFM Intergroup). Blood 2005; 106 (Suppl) Abstract 421.
16. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study. Blood 2004; 103: 3960-3963.
17. 123-labeled serum amyloid P component. N Engl J Med 1990; 323: 542-543.
18. Linke RP. Highly sensitive diagnosis of amyloid and variuos amyloid syndromes using congo red fluorescence. Virchow Arch Path Anat 2000; 436: 439-448.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
20. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
21. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381-388.
22. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain myloidosis: A single centre prospective phase II study. Br J Haematol 2004; 127: 543-551.
23. Perz JB, Schonland SO, Hundemer M, Zeier M, Linke RP, Ho AD et al. High-dose melphalan and stem cell recue for kidney AL amyloidosis. In: Grateau G, Kyle RA, Skinner M (eds). Amyloid and amyloidosis. CRC Press: Boca Raton, FL, 2005, pp 118-120.
24. Moreau P, Leblond V, Baurquelot P. Prognostic factors of survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL myloidosis: A report on 21 patients. Br J Haematol 1998; 101: 766-769.